JD5037

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP23654CAS No. ：1392116-14-1Purity：98%

Get Quotation Now

Tel: 0086-17754423994 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	1392116-14-1	Cat. No.	BCP23654
Name	JD5037
Synonyms	JD-5037; JD 5037;
SMILES	NC([C@H](C(C)C)/N=C(NS(=O)(C1=CC=C(Cl)C=C1)=O)N2N=C(C3=CC=C(Cl)C=C3)[C@@H](C4=CC=CC=C4)C2)=O
Chemical Name
Formula	C27H27Cl2N5O3S	M. Wt	572.505
Purity	98%	Storage	Store at 4-8°C
Description	JD5037 is a peripherally restricted (PR) cannabinoid-1 receptor blocker. JD5037 is an antiobesity drug candidate which acts as a peripherally-restricted cannabinoid inverse agonist at CB1 receptors. It is very selective for the CB1 subtype, with a Ki of 0.35nM, >700-fold higher affinity than it has for CB2 receptors. In animal studies, JD5037 does not readily cross the blood brain barrier and thus is not expected to produce the psychiatric side effects in humans which led to the withdrawal of rimonabant from the market. Its antiobesity effects are believed to be mediated by blockade of peripheral CB1 receptors, resulting in decreased leptin expression and secretion and increased leptin clearance by the kidneys.